TG Therapeutics Inc
TGTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.96B
Close$
$0.44
99.1% downside
Current Fair Value
99.1% downsideOvervalued by 99.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.96 Billion |
|---|---|
| Enterprise Value | $7.55 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $3.1 |
| Beta | 1.6 |
| Outstanding Shares | 144,439,370 |
Return
| Return on Equity | 79.21% |
|---|---|
| Return on Assets | 30.21% |
| Return on Invested Capital | 11.68% |
Valuation & Multiples
| P/E Ratio | 16.36 |
|---|---|
| PEG | 5.63 |
| Price to Sales | 12.18 |
| Price to Book Ratio | 12.18 |
| Enterprise Value to Revenue | 10.79 |
| Enterprise Value to EBIT | 48.22 |
| Enterprise Value to Net Income | 16 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 3, 2026
EPS Estimate
$0.31
Average shareholder expectationRevenue Estimate
$229.77 M
Average shareholder expectationNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$0.38
Average shareholder expectationRevenue Estimate
$246.37 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 122.08% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 5.20%▼ 67.76% |
|---|---|
| Total Invested | $411.80M▼ 88.23% |
| Investors Holding | 129▼ 256.00% |
ESG Score
No data
About TG Therapeutics Inc
CEO: Michael Weiss Relevant Senate Committees
Finance
Oversees Medicare and Medicaid (CMS); determines reimbursement rates and drug pricing legislation, which are primary drivers of biotech revenue.
Health, Education, Labor, and Pensions
Directly oversees the FDA and NIH; members have access to non-public information regarding drug approval processes and safety standards.
Special Committee on Aging
Highly active in drug pricing investigations and Medicare coverage issues, which are critical for companies treating chronic diseases.